SEC Form 4 · accession 0001209191-17-051260
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bryan Irving
Officer — SVP, Research
Period of report
Sep 1, 2017
Accepted (ET)
Sep 5, 2017 · 4:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 1, 2017 | A | 15,000 | $0.00 | A | 15,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $0.00 | Sep 1, 2017 | A | 80,000 | A | — | Sep 1, 2027 | Common Stock | 80,000 | 80,000 | D |
Explanation of responses
- F1Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of September 1, 2018, 2019 and 2020, provided the reporting person remains employed by Five Prime Therapeutics, Inc. (the "Company") through each such date.
- F2One fourth (1/4th) of the shares underlying the option will vest on September 1, 2018, and the remainder of the shares underlying the option vest at a rate of one forth-eighth (1/48th) per month thereafter, provided the reporting person remains employed by the Company through each such date.